CordenPharma Small Molecules Platform

CordenPharma Small Molecules Platform

Products
CordenPharma Small Molecules Platform
CordenPharma Small Molecules Platform

Information

Full-Service Partner of Choice from Advanced Intermediates to Drug ProductsIntegrated network of cGMP facilities across Europe and US1,200 m3 of volumetric capacity in 20 L - 28,000 L reactors with various materials of constructionClinical (Phase I-III) and ongoing commercial supply to multiple markets around the world (including US, Europe and Japan)Kilo to Multi-ton production volumes per annumProcess development capabilities (including flow / continuous manufacturing)All sites FDA and EMEA approved facilities with long history of successful regulatory and customer auditsStrong EHS programs in place at sites
Main Categories
APIs (Active Pharmaceutical Ingredients)Custom ManufacturingIntermediates, Fine and Specialty Chemicals
All Categories
Advanced IntermediatesAPI Contract ManufacturingAPIs (Active Pharmaceutical Ingredients)Custom ManufacturingIntermediates, Fine and Specialty Chemicals
Distribution areas
OceaniaNorth America (USA, Canada)East Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied from
United States
Corden Pharma International GmbHCordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization. With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency). The CordenPharma Group is comprised of 12 facilities across Europe and North America. In the 2022 financial year, the organization generated sales of 870 million Euros and had over 3,000 employees. Please visit cordenpharma.com for more information.

Log in

See all the content and easy-to-use features by logging in or registering!